Item 7.01 Regulation FD Disclosure. On September 9, 2026, HCW Biologics Inc. issued Amendment No. 1 to Preliminary Proxy Statement, a copy of which is included in this Form 8-K as Exhibit 10.1.…
HCW Biologics Inc. (“HCW Biologics” or the “Company”) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. We have created novel compounds that represent a new class of drugs that we believe have the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. Among other things, we have begun commercialization of certain commercial-ready proprietary compounds for use as reagents in the production of immunotherapeutics for the treatment of infectious diseases and cancer. We want our products to improve patients’ healthspan as well as their quality of life, and possibly extend longevity.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item
7.01 Regulation FD Disclosure.
On
September 9, 2026, HCW Biologics Inc. issued Amendment No. 1 to Preliminary Proxy Statement, a copy of which is included in this Form
8-K as Exhibit 10.1.
The
information furnished in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference
in such a filing.
Item 8.01Item 8.01 - Other Events
Item
8.01 Other Events.
On
September 9, 2026, HCW Biologics Inc. (the “Company”) filed Amendment No. 1 to Preliminary Proxy Statement (the “Amendment”),
which amends and restates the Preliminary Proxy Statement originally filed with the Securities and Exchange Commission on September 8,
2026 (the “Original PRE 14A”). After considering stockholder feedback, the board of directors of the Company decided not
to seek stockholder approval of Proposal No. 2 in the Original PRE 14A, which would have sought stockholder approval of an amended performance-based
equity plan for the Company’s eligible officers, directors and employees, and to remove that proposal through the Amendment. In
addition, the Amendment changes the date of the Special Meeting of Stockholders, the record date for the meeting and certain other dates
set forth in the Original PRE 14A. Except as described above, no other substantive changes were made to the Original PRE 14A.
The
foregoing description of the Amendment is qualified in its entirety by reference to the full text of Amendment No. 1 to Preliminary Proxy
Statement filed on September 9, 2026.